Jinsen Liang

Wuhan, 430071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer.

Journal: European journal of medicinal chemistry

Published: February 26, 2026

Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression.

Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression.

Journal: Journal of medicinal chemistry

Published: November 11, 2025

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer.

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer.

Journal: Journal of medicinal chemistry

Published: May 28, 2025

Discovery of ERα-targeting PROTACs with intrinsic fluorescence for precision theranostics of breast cancer.

Discovery of ERα-targeting PROTACs with intrinsic fluorescence for precision theranostics of breast cancer.

Journal: RSC medicinal chemistry

Published: April 02, 2025

Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.

Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.

Journal: Journal of medicinal chemistry

Published: May 22, 2024

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer.

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer.

Journal: European journal of medicinal chemistry

Published: February 20, 2024

Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.

Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.

Journal: European journal of medicinal chemistry

Published: March 15, 2023

Identification of a novel acylthiourea-based potent broad-spectrum inhibitor for enterovirus 3D polymerase in vitro and in vivo.

Identification of a novel acylthiourea-based potent broad-spectrum inhibitor for enterovirus 3D polymerase in vitro and in vivo.

Journal: Antiviral research

Published: January 28, 2023

Antiviral PROTACs: Opportunity borne with challenge.

Antiviral PROTACs: Opportunity borne with challenge.

Journal: Cell insight

Published: December 23, 2022

Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus.

Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus.

Journal: Cell insight

Published: April 27, 2022

Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).

Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).

Journal: Journal of medicinal chemistry

Published: February 25, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026